Epigenetic
changes in cancer treatment

A new frontier of precision targeting in lethal cancers

EP31670
CLINICAL
EP31670
CLINICAL

EP31670 (= NEO2734)

A first-in-class oral once daily drug for Myelofibrosis and other cancers

Studies with the dual BRD4 and p300/CBP inhibitor EP31670 (NEO2734) are now underway in Myelofibrosis in combination with a JAK inhibitor. We are also studying patients with other myeloid malignancies. Guided by our experience in solid tumor patients where we are seeing excellent tolerability and early signs of efficacy in NUT carcinoma (BRD protein targeted therapy). We believe that our unique characteristics will prove superior to BET inhibitor pelabresib (recently acquired by Novartis) both with respect to pharmacodynamics as well as pharmacokinetics.

Clinical trials are ongoing at MD Anderson Cancer Center, Mayo Clinic (all three sites), Dana-Farber Cancer Institute and University of Washington/Fred Hutchinson Cancer Research Center with other leading cancer centers soon also joining.

Read more

Clinical

Primary indications where all are backed by unprecedented preclinical data.

  • Myeloid (blood cancer) malignancies

  • Metastatic castrate resistant prostate cancer (mCRPC)

  • NUT midline carcinoma (NC)

  • Pancreatic cancer (PDAC)

  • Breast cancer (TNBC and ER+)

Read more

IND 158612

IND in January 2022: ” study may proceed”

References

Below are links to articles regarding EP31670 (=NEO2734) 

(additional publications forthcoming)